Preclinical versus clinical neuroprotection.
Grünblatt
Edna
E
Department of Neurochemistry, Clinic and Polyclinic of Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-University of Würzburg, Würzburg, Germany.
Schlösser
Robert
R
Gerlach
Manfred
M
Riederer
Peter
P
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D002986:Clinical Trials as Topic; D018491:Dopamine Agonists / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
D000975:Antioxidants; D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D018691:Excitatory Amino Acid Antagonists; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents